Phase 3 study designed with total hip BMD primary endpoint assessed at 12 months, rather than at 24 months. EB613 single ...
Ultragenyx Pharmaceutical Inc. ( RARE) TD Cowen 46th Annual Health Care Conference March 2, 2026 1:50 PM EST ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results